Protocol # GS-US-321-0106: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secon

  • Flamm, Steven L (PD/PI)

Project: Research project

Project Details

Effective start/end date3/14/138/31/19


  • PPD Development (GS-US-321-0106 // GS-US-321-0106)
  • Gilead Sciences, Inc (GS-US-321-0106 // GS-US-321-0106)